Rolipram attenuates MK-801-induced deficits in latent inhibition

Jennifer A. Davis, Thomas J. Gould

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.

Original languageEnglish (US)
Pages (from-to)595-602
Number of pages8
JournalBehavioral Neuroscience
Volume119
Issue number2
DOIs
Publication statusPublished - Apr 1 2005

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Behavioral Neuroscience

Cite this